REMD-477

Phase 2Small molecule

RREMD Biotherapeutics, Inc.

REMD-477 is one of 51 small molecule programs targeting Type 1 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 1 Diabetes MellitusCompleted

Type 1 Diabetes MellitusPhase 2

Completed

Competition

Competitive Landscape

64 competitors in Type 1 Diabetes Mellitus

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

2 2

Mounjaro

Eli Lilly

Approved

1 3

Cibinqo

Farxiga

Olumiant

Prevacid

Diabeta

Cellcept

Calciferol

Opzelura

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 1 Diabetes2 trials

Metabolic Pathways of GRA in Patients With Type 1 Diabetes

Completed·UUniversity of California, San Diego·Phase 1/2·NCT03919617·4 enrolled

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

Completed·UUniversity of California, San Diego·Phase 1/2·NCT04545411·12 enrolled

Type 1 Diabetes Mellitus2 trials

Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

Completed·RREMD Biotherapeutics, Inc.·Phase 2·NCT03117998·154 enrolled

Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

Completed·RREMD Biotherapeutics, Inc.·Phase 1·NCT02715193·21 enrolled

Hyperglycemia1 trial

A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

Terminated·—·Phase 1·NCT04253223·1 enrolled

Type 2 Diabetes Mellitus1 trial

Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus

Completed·RREMD Biotherapeutics, Inc.·Phase 1/2·NCT02455011·75 enrolled

Metabolism1 trial

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT05093517·4 enrolled

2 more indications

Breast Cancer1 trial

Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

Terminated·—·Phase 1·NCT04330625·1 enrolled

Unspecified1 trial

Effects of GRA in Patients With Type 1

Active, not recruiting·UUniversity of California, San Diego·Phase 2·NCT04779645·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for REMD-477. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REMD-477 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REMD-477. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — REMD Biotherapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RREMD Biotherapeutics, Inc.

REMD-477

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 1 Diabetes2 trials

Type 1 Diabetes Mellitus2 trials

Hyperglycemia1 trial

Type 2 Diabetes Mellitus1 trial

Metabolism1 trial

Breast Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News